Myriad Board Under Fire For Allegedly Overselling Gene Test
A shareholder in Myriad Genetics Inc. told a Delaware federal court that company executives and directors lied to investors for years about a study of one of its flagship products, a...To view the full article, register now.
Already a subscriber? Click here to view full article